AI주식인사이트AI Stock Insight
C

HLB펩

196300KOSDAQ기초 의약물질 제조업

52.3 / 100

Reference Date: 2026-06-10

Financial Score17.0 / 40
News Sentiment21.3 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but Operating Profit is on a declining trend. Plunged 28.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Pep is a company specializing in the synthesis of amino acids, peptides, and proteins, offering CDMO (Contract Development and Manufacturing Organization) services for pharmaceutical production. Utilizing solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS) technologies, the company manufactures APIs (Active Pharmaceutical Ingredients) for new drug development and clinical trials, adhering to GMP (Good Manufacturing Practice) and CMC (Chemistry, Manufacturing, and Controls) standards.

Number of Employees

88people

Average Salary

35.2M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 27.714.0Point
PBR
1.77Industry Average 1.742.5Point

Higher than industry avg (caution)

ROE
-4.13Industry Average -6.033.5Point

Below industry avg

Debt Ratio
2.72Industry Average 6.626.5Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼4.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼7.8% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -55.2% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 4,850Won52-week high 9,41052-week low 4,840
1-month return0.0Point

1m -28.89% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral주식등의대량보유상황보고서(일반)2026-05-29
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-05-20
  • Neutral분기보고서 (2026.03)2026-05-15